Citable company snapshot
Abbott Laboratories's latest SEC-sourced 2026-06-30 period shows $12.59B in revenue and $928.00M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| Revenue | Jun 30, 2026 | $12.59B | $11.16B | +12.8% |
| Gross Profit | Dec 31, 2019 | $4.40B | $4.23B | +3.8% |
| Operating Income | Jun 30, 2026 | $1.69B | $1.34B | +25.9% |
| Net Income | Jun 30, 2026 | $928.00M | $1.10B | -15.6% |
| Operating Cash Flow (computed) | Jun 30, 2026 | $2.49B | $1.31B | +89.2% |
| Free Cash Flow (computed) | Jun 30, 2026 | $1.99B | $916.00M | +117.4% |
Source: SEC EDGAR financial statements; period Jun 30, 2026; filed Jul 28, 2026; accession 0001628280-26-050134.
ABT company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.